Clinical experience with the use of anti-CdtB and anti-vinculin antibodies in patients with diarrhea in Mexico

Circulating anti-CdtB/anti-vinculin antibodies have been validated as biomarkers to distinguish IBS-D from IBD, but there is no experience with them in Latin America. The analysis was carried out on patients seen at a FGIDs/motility clinic over the last 7 months for diarrhea with abdominal pain and/...

Full description

Saved in:
Bibliographic Details
Published in:Revista de gastroenterología de México 2016-10, Vol.81 (4), p.236-239
Main Authors: Schmulson, M, Balbuena, R, Corona de Law, C
Format: Article
Language:eng ; spa
Subjects:
Adolescent
Adult
Aged
Aged, 80 and over
Antibodies, Blocking - therapeutic use
Bacterial Toxins - antagonists & inhibitors
Bacterial Toxins - immunology
Diarrhea - drug therapy
Diarrhea - etiology
Female
Humans
Irritable Bowel Syndrome - complications
Irritable Bowel Syndrome - drug therapy
Male
Mexico
Middle Aged
Retrospective Studies
Vinculin - antagonists & inhibitors
Young Adult
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Circulating anti-CdtB/anti-vinculin antibodies have been validated as biomarkers to distinguish IBS-D from IBD, but there is no experience with them in Latin America. The analysis was carried out on patients seen at a FGIDs/motility clinic over the last 7 months for diarrhea with abdominal pain and/or bloating who were tested for these antibodies. The patients were diagnosed according to the Rome III criteria or with organic disorders, and those presenting with IBS were further classified as post-infectious (PI) or non-PI-IBS. Thirty patients were studied. Positive biomarkers were found in IBS-D and IBS-D Overlap (58.8%) and IBS-M (33.3%), with no differences between PI-IBS (71.4%) vs. non-PI-IBS (41.7%) subjects (P=.21). There was no positivity in patients with other FGIDs or organic diarrhea, except for one with small intestinal bacterial overgrowth (SIBO). Our findings support the use of this test as a first-line diagnostic tool to confirm the presence of IBS-D/IBS-M according to the Rome III criteria.
ISSN:0375-0906
DOI:10.1016/j.rgmx.2016.07.001